Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Locations
- 🇺🇸
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1148
- Registration Number
- NCT00002757
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
🇬🇧Children's Hospital - Sheffield, Sheffield, England, United Kingdom
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- Interventions
- Biological: dactinomycinBiological: sargramostimDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: etoposideDrug: mercaptopurineDrug: prednisoneDrug: mitoxantrone hydrochlorideDrug: pegaspargaseDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 179
- Registration Number
- NCT00003650
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-01-21
- Target Recruit Count
- 1500
- Registration Number
- NCT00003728
- Locations
- 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 58
- Registration Number
- NCT00005601
- Locations
- 🇺🇸
CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00015951
- Locations
- 🇺🇸
Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- German CML Study Group
- Target Recruit Count
- 750
- Registration Number
- NCT00002771
- Locations
- 🇩🇪
III Medizinische Klinik Mannheim, Mannheim, Germany
STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT00015834
- Locations
- 🇺🇸
University of California at Los Angeles (UCLA ), Los Angeles, California, United States
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00005802
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.